Humanwell Healthcare (600079.SH): RFUS-188 injection has entered Phase II clinical trials.

Humanwell Healthcare (600079.SH) announced that its controlling subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu," in which the company holds an 80% share), has recently published the phase II clinical trial registration information for RFUS-188 injection on the National Medical Products Administration's Clinical Trial Registration and Information Disclosure Platform. Trial Name: A multicenter, randomized, double-blind, parallel, placebo/positive-controlled, two-stage design clinical trial to evaluate the efficacy and safety of RFUS-188 injection for postoperative analgesia in abdominal surgery. Objective: (1) To explore the effective dose of RFUS-188 injection for postoperative analgesia (Part A); (2) To evaluate the efficacy and safety of RFUS-188 injection for postoperative analgesia (Part B). Secondary Objective: To explore the PK/PD characteristics of repeated doses of RFUS-188 injection for postoperative analgesia.